Figure 3

(a) SCID-synth-hu mice were treated intraperitoneally with bortezomib (1 mg/kg)+dexamethasone (1 mg/kg). The black arrows indicate the time of treatment. (b) H&E staining of a MM-bearing PCLS, engrafted with primary MM cells, following Bort+Dex treatment showed diffuse stromal and intracellular calcification demonstrating massive apoptosis. (c) (1) H&E staining of a retrieved PCLS showed vessels of variable size (black circles). (2) Immunohistochemistry of a PCLS coated with BMSCs demonstrated reactivity with an anti-CD31/JC70A (Dako) specific for human CD31 (black arrow). Appropriate positive control tissues were added on each automated immunohistochemistry run to confirm antibody specificity. Negative control section included normal rabbit serum as a substitute for the primary antibody. (3) H&E staining of a retrieved PCLS engrafted with BMMCs shows an active site of vasculogenesis within an area of MM cell growth (yellow arrow). (4) H&E staining of a retrieved PCLS coated with BMSCs revealed the presence of a neosynthesized ECM inside the pores.